BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 5, 2003
View Archived Issues
Invitrogen Buying Technology From Vertex Unit For $95M Cash
Invitrogen Corp. agreed to pay $95 million in cash to purchase certain product lines and technology rights from PanVera LLC, a wholly owned subsidiary of Vertex Pharmaceuticals Inc. (BioWorld Today)
Read More
Cell Genesys Cuts Gene Therapy Programs To Focus On Cancer
Read More
MaxCyte, Northern Therapeutics Enter Gene Therapy Delivery Deal
Read More
TransTech Translates Progress Into $24.5M Secured Investment
Read More
Other News To Note
Read More